FDA approves first treatment for desmoid tumors

The new drug, Ogsiveo, is made by Springworks and targets desmoid tumors, a localized cancer that invades soft tissue and muscle.

November 28, 2023 Check out STAT+

Sponsored By

Andrew Harnik/AP STAT+ | Springworks wins FDA approval for drug to treat desmoid tumors The new drug, called Ogsiveo, is made by Springworks Therapeutics. It's the company's first approved medicine. By Adam Feuerstein New research supports potential link between low-level lead exposure and liver injury Some researchers increasingly think the chronic disease epidemic might be driven at least in part by the very environments we inhabit. By Isabella Cueto How to spot when drug companies spin clinical trial results STAT has released the update of its Guide to Interpreting Clinical Trial Results, to help consumers of company readouts navigate the process. By STAT Staff

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser